Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.

Date publication

juillet 2019

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VELTEN Michel , Dr LORGIS Véronique

Tous les auteurs :
Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, Vanlemmens L, Leheurteur M, Lévy C, Laborde L, Uwer L, D'hondt V, Berchery D, Lorgis V, Ferrero JM, Perrocheau G, Courtinard C, Mouret-Reynier MA, Velten M, Breton M, Parent D, Chabaud S, Robain M, Bachelot T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31330488

Résumé

For luminal metastatic breast cancer (MBC), endocrine therapy (ET) is the recommended initial treatment before chemotherapy. Our objective was to evaluate the efficacy of multiple ET lines in a real-life study.

Mots clés

Breast cancer, Endocrine therapy, Exceptional response, Metastatic, Real-world data

Référence

Eur. J. Cancer. 2019 Jul 19;118:131-141